



The Nifty previous session ended 1.77% down at 14,359.45. It opened huge gap-down and found support around 14,190 levels followed by minor recovery in the second half towards finishing off with a hammer candle. 100 Exponential MA placed around 14,150 levels is likely to act as the major demarcation between bulls and bears. Immediate resistance is placed around 14,450 levels. Chart pattern broader trading range is likely to be 14,250-14,600.

On the Nifty hourly chart; direction of the oversold leading indicators pointing towards range-bound oscillation with a positive bias within the price range of 14,250-14,600. Midway resistance is placed around 14,450 levels.

Nifty patterns on multiple time frames suggest; ending the day with a Hammer candle on daily suggests buyers are still active on dips. 100 Exponential MA is placed around 14,150 levels.

Nifty Crucial Supports & Resistances-
Supports- 14250, 14150 Resistances- 14450, 14600

Open Positional Calls-

T+3 Positional Buy-
|Cash Segment| LUPIN @ 1060-1050, TGT- 1110, Closing SL- 1020

T+5 Positional Buy-
|Cash Segment| RIL @ 1905-1900, TGT- 1980, Closing SL- 1860

T+3 Positional Buy-
|Cash Segment| PVR @ 1050-1040, TGT- 1100, Closing SL- 1010

T+3 Positional Buy-
|Cash Segment| BANK OF INDIA @ 65-64, TGT- 72, Closing SL- 60

T+5 Positional Buy-
|Cash Segment| HAVELLS @ 985-980, TGT- 1040, Closing SL- 950

Key Contents	Page No.
Result Update	4
Domestic News	5

Nifty Intraday Chart



Market in Retrospect

Indian equity benchmarks and the rupee turned worst performers in Asia as a worsening coronavirus crisis sparked investor concerns over a nascent economic recovery and corporate profits.

NIFTY index ended 1.77% lower at 14,359. The broader markets represented by the NIFTY 500 Index ended 1.80% lower, ending at 12,076. Among the sectorial indices, NIFTY Pharma was the only top gainer, gaining by 0.17%. NIFTY PSU Bank was the top loser, losing by 4.31%.

Dr. Reddy's Lab was the top gainer, gaining by 1.53%, followed by Britannia Industries and Cipla which gained by 1.25% & 0.88% respectively. Adani Ports & SE was the top loser, losing by 4.57%, followed by Power Grid and ONGC, which fell by 4.12% & 3.96% respectively.

The Advance: Decline ratio stood at 379:1595

Market Turnover (In Crore) 19-04-2021

Name	Last	Previous
NSE Cash	68103.17	66091.79
NSE F&O	3083299.97	2170508.86
BSE Cash	3,909.45	3,883.47
BSE F&O	*NA	18.02

FII Derivatives Flow (In Crore) 16-04-2021*

Instrument	Purchase	Sale	Net
Index Future	4857.22	4802.52	54.7
Index Option	245564.54	242436.64	3127.9
Stock Future	12341.74	11292.62	1049.12
Stock Option	14475.95	14679.87	203.92

Institutional Flow (In Crore) 16-04-2021*

Institution	Purchase	Sale	Net
FII	7512.32	7074.81	437.51
DII	5523.58	4866.03	657.55

*Data not updated till 6pm

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Dr. Reddy'S Lab	1.53	4.37	1843928	2279615
Britannia Industries	1.25	1.45	560398	558742
Cipla	0.88	7.16	17805574	15992550
Wipro	0.76	5.03	43809855	36665300
Infosys	0.65	5.45	12508028	15502960

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Kotak Bank	3.59	5.47	3865423	3209126
Hero Motocorp	3.78	4.37	740714	704882
ONGC	3.96	0.72	19166492	24088810
Power Grid	4.12	3.41	10352810	9261970
Adani Ports & SE	4.57	12.46	22935238	34125870

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	47949.42	882.61	1.81	3.31	3.83	2.93	51.79
Nifty	14359.45	258.40	1.77	3.20	2.61	1.11	54.96
BSE M Cap	19768.84	388.52	1.93	4.78	1.38	4.31	67.19
BSE S Cap	20674.07	344.48	1.64	4.27	0.99	10.94	91.41
Nifty MC 100	23256.35	504.30	2.12	5.10	0.67	5.86	78.25
BSE Auto	21520.49	608.51	2.75	3.83	6.44	5.91	67.08
BSE Capgoods	19797.71	631.73	3.09	6.10	6.12	0.72	60.58
BSE FMCG	12775.00	143.81	1.11	2.20	1.59	0.09	16.09
BSE Metal	15880.28	226.75	1.41	1.71	14.42	30.27	141.58
BSE Oil&Gas	14405.89	343.68	2.33	3.52	5.51	3.52	28.37
BSE Healthcare	23106.34	99.40	0.43	1.68	12.47	5.73	55.18
BSE Power	2380.94	71.45	2.91	4.24	5.90	11.99	58.25
BSE Realty	2384.87	98.33	3.96	9.66	8.98	10.84	64.95
BSE ConsDur	31972.76	457.45	1.41	3.94	1.42	3.70	56.42
BSE Bank	35399.99	887.33	2.45	3.73	7.98	3.62	49.46
BSE IT	26785.69	44.12	0.16	4.61	3.04	2.59	110.57

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.57	0.01	0.66	5.78	8.81	44.17	144.57
UK	0.75	0.01	1.44	4.56	10.14	160.55	147.70
Brazil	4.04	0.04	0.93	3.99	1.87	13.07	4.33
Japan	0.09	0.01	6.45	19.44	23.01	52.63	222.22
Australia	1.72	0.02	1.04	3.16	4.82	56.80	100.12
India	6.08	0.01	0.15	1.13	1.84	2.95	4.22
Switzerland	0.23	0.00	0.00	8.16	5.86	49.55	50.66
Germany	0.25	0.01	4.20	14.33	14.63	52.28	46.82

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.88	0.53	0.70	0.23	3.15	2.28	2.23
USD Index	91.11	0.44	0.48	1.11	0.88	0.68	8.69
YUAN	6.51	0.01	0.21	0.63	0.03	0.43	8.70
GBP	1.39	0.01	0.48	1.14	0.19	1.97	11.70
EUR	1.20	0.01	0.47	1.07	1.13	0.74	10.84
YEN	108.15	0.65	0.60	1.14	0.68	3.93	0.49

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2385.00	62.00	2.67	14.39	4.56	35.05	217.58
Baltic Dirty	605.00	3.00	0.49	3.82	19.12	21.98	47.57
SG Dubai HY	0.86	0.04	4.44	22.86	104.76	15.69	72.08

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34200.67	164.68	0.48	1.18	4.82	10.57	41.08
Nasdaq	14052.34	13.58	0.10	1.09	6.33	6.48	62.45
S&P 500	4185.47	15.05	0.36	1.37	6.96	10.18	45.60
FTSE100	7030.07	15.27	0.22	2.11	4.86	4.79	21.56
CAC40	6303.39	20.40	0.32	2.37	5.16	12.66	40.20
DAX	15426.12	20.32	0.13	1.48	5.60	11.76	45.30
Mexico IPC	48726.98	212.87	0.44	2.31	3.61	7.10	40.25
Brazil Bovespa	121113.9	413.20	0.34	2.93	4.21	0.40	53.33
Russian RTS	1486.99	11.15	0.74	3.73	0.80	1.04	37.75
Japan Nikkei	29685.37	2.00	0.01	0.50	0.36	3.67	49.19
Hang Seng	29106.15	136.44	0.47	2.29	0.40	1.81	19.39
Taiwan Index	17263.28	104.47	0.61	2.39	7.42	8.73	62.91
Shanghai Comp	3477.55	50.93	1.49	1.89	2.14	2.49	22.51
KOSPI	3198.84	0.22	0.01	2.02	5.24	3.43	67.08
Malaysia KLCI	1600.29	8.09	0.50	0.51	1.59	0.10	13.71
Jakarta Comp	6052.54	33.72	0.55	1.75	4.78	4.26	30.59
Philippine SE	6459.76	35.05	0.54	0.90	0.37	10.26	11.57
Thai Exch	1574.91	25.95	1.68	1.18	0.70	3.44	27.09

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	62.93	0.21	0.33	5.39	2.44	18.76	244.39
BRENT Crude	66.58	0.20	0.30	5.20	3.45	19.90	68.87
Natural Gas	2.74	0.05	2.01	6.76	6.55	5.32	10.60

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1787.52	10.73	0.60	3.14	2.41	2.88	6.21
Silver(\$/Ounce)	26.18	0.20	0.77	5.44	0.31	3.73	72.39
Aluminium	2301.95	20.65	0.89	2.46	5.69	15.61	56.09
Copper	9227.00	70.25	0.76	3.27	2.93	16.25	80.28
Zinc	2834.30	8.55	0.30	0.94	1.57	5.85	47.06
Lead	2027.10	28.85	1.44	3.62	6.17	2.42	21.11

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	132.30	1.10	0.84	1.77	0.95	0.92	7.56
Cotton	86.23	1.20	1.41	5.79	0.59	4.09	48.14
Sugar	16.49	0.08	0.48	7.36	6.73	12.48	43.77
Wheat	659.00	4.00	0.61	4.40	6.42	0.11	21.31
Soybean	1434.75	12.25	0.86	4.04	2.26	4.78	68.20

Bajaj Consumer Care Ltd

Bajaj Consumer Care reported over two-fold growth in consolidated net profit at INR54.67 crore for the fourth quarter ended March 31, 2021. The company reported a net profit of INR23.29 crore for January-March period a year ago. Its revenue from sale of goods was higher at INR244.86 crore as against INR172 crore in the year-ago period. Total expenses of Bajaj Consumer Care, which operates mainly in the beauty care category, were at INR189.17 crore as against INR158.69 crore, up 19.21 per cent. For 2020-21, Bajaj Consumer's net profit was up 20.76 per cent at INR223.13 crore as against INR184.77 crore a year ago. Its revenue from the sale of goods last fiscal year was at INR905.15 crore, up 9.61 per cent. It was INR825.75 crore in 2019-20.

ACC Ltd.

ACC reported that its net profit in the March quarter was up 74 per cent at INR563 crore against INR323 crore logged in the same period last year, mainly on better realisation. Revenue from sales increased 23 per cent to INR4,213 crore (INR3,433 crore). Cement sales during the quarter under review was up 22 per cent at 8 million tonne while EBITDA jumped 47 per cent to INR860 crore. Power and fuel cost was down by INR83 per tonne to INR999 while logistics expenses dipped by INR32 to INR1,308 per tonne. The cost savings and lower employee cost pushed up EBITDA per tonne to INR1,028 (INR798). Cement prices during the quarter was up six per cent to INR4,876 a tonne (INR4,579) on sale of premium products. The execution of the greenfield growth project at Ametha in Madhya Pradesh and associated grinding units are expected to be completed by June 2022.

Jaguar Land Rover expects China premium car sales to grow this year

Jaguar Land Rover expects premium car sales to continue to grow this year in China. Tim Howard was speaking to reporters at the 2021 Shanghai Auto Show. Jaguar Land Rover will start making first plug-in hybrid vehicles in China this year. Overall auto sales in China surged in March for a 12th straight month, as the world's biggest car market leads the sector's recovery from the COVID-19 pandemic.

EU official looks to align with India on 5G to protect democracy

The European Union will discuss 5G technology rollouts and the establishment of global security standards when leaders meet with India next month, as concerns grow about the dominance of Chinese telecom giants. Europe wants to work with democratic partners including India to establish open and transparent standards as nations prepare to move to the new security protocol that should be part of every 5G value chain. Prime Minister Narendra Modi is scheduled to attend the India-EU summit in Portugal on May 8 to meet leaders from the 27-member bloc of nations for discussions on trade and security issues. The EU is India's largest trading partner. India and many European countries, along with the U.S., have sought to distance their next generation telecom infrastructure from companies including Huawei Technologies Co. and ZTE Corp. amid concerns over their links with the Chinese government.

Jubilant Pharmova arm completes studies using novel oral formulation of Remdesivir

Jubilant Pharmova on its arm Jubilant Pharma has successfully completed studies using a novel oral formulation of Remdesivir used for treatment of COVID-19 against the available injectable formulation of the antiviral drug in India. Jubilant Pharma has successfully completed safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral formulation of Remdesivir against the commercially available injectable formulation of Remdesivir. Jubilant has sought authorisation for additional studies for this novel oral formulation from the Drug Controller General of India. Jubilant is hoping to provide an affordable, more convenient, easy-to-administer and potentially effective treatment option for COVID-19 patients. The proposed oral treatment is expected to be for five days, a duration similar to the injectable dosage. Remdesivir is the first and the only anti-viral drug fully approved by the USFDA for the treatment of patients with COVID-19 requiring hospitalization.

Future Retail's debt plan passage eases some immediate woes

Indian supermarket-operator Future Retail Ltd. approved a debt resolution plan that eases some immediate concerns as a legal battle with partner Amazon.com Inc. threatens to delay an asset sale to Reliance Industries Ltd. Future Retail's board agreed to a proposition to restructure its secured bank debt and three rupee-denominated bonds, according to an exchange. There are signs that the broader concerns about Future Retail's tussle with Amazon may continue to weigh on the debt. India's top court scheduled a final hearing in the matter to May 4 and said it will decide the case for once and for all.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com